Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trappsol Cyclo in Niemann-Pick Disease Type C1
NCT04860960Phase 3Active, not recruiting
- Sponsor
- Cyclo Therapeutics, Inc.
- Start
- Jul 2021
- Primary completion
- Jun 2025
- Modality
- Nanoparticles, Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of Trappsol Cyclo in Niemann-Pick disease type C1 (NPC1), sponsored by Cyclo Therapeutics, Inc.. Started Jul 2021; status: active, not recruiting.
02
Drugs
Trappsol Cyclo
03
Conditions
Niemann-Pick disease type C1 (NPC1)
Beyond the preview
Go deeper on NCT04860960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04860960.